Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.

Caryl and Israel Englander Institute for Precision Medicine New York NY USA

Department of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Department of Oncology Laboratory of Tumor Immunology and Immunotherapy Leuven Cancer Institute KU Leuven Leuven Belgium

Department of Radiation Oncology Weill Cornell Medical College New York NY USA

Division of Gynecological Oncology Department of Obstetrics and Gynecology University Hospital Leuven Leuven Belgium

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Sandra and Edward Meyer Cancer Center New York NY USA

Sotio Biotech Prague Czech Republic

UCLA David Geffen School of Medicine and Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles California USA

000      

00000naa a2200000 a 4500

001      

bmc22012153

003      

CZ-PrNML

005      

20220506131508.0

007      

ta

008      

220425s2021 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1136/jitc-2021-002873 $2 doi

035    __

$a (PubMed)34645669

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Fucikova, Jitka $u Sotio Biotech, Prague, Czech Republic fucikova@sotio.com $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/000000028423479X $7 xx0116819

245    10

$a Immunological configuration of ovarian carcinoma: features and impact on disease outcome / $c J. Fucikova, A. Coosemans, S. Orsulic, D. Cibula, I. Vergote, L. Galluzzi, R. Spisek

520    9_

$a Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.

650    _2

$a epiteliální ovariální karcinom $x imunologie $7 D000077216

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a imunosupresivní léčba $x metody $7 D007165

650    _2

$a imunoterapie $x metody $7 D007167

650    _2

$a výsledek terapie $7 D016896

650    _2

$a nádorové mikroprostředí $7 D059016

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Coosemans, An $u Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium $1 https://orcid.org/0000000273214339

700    1_

$a Orsulic, Sandra $u UCLA David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA

700    1_

$a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000163879356 $7 jo20000074072

700    1_

$a Vergote, Ignace $u Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium

700    1_

$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA $u Sandra and Edward Meyer Cancer Center, New York, NY, USA $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA

700    1_

$a Spisek, Radek $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic

773    0_

$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 9, č. 10 (2021)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34645669 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506131500 $b ABA008

999    __

$a ok $b bmc $g 1789656 $s 1163354

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 9 $c 10 $e - $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262

GRA    __

$a I01 BX004974 $p BLRD VA $2 United States

GRA    __

$a R01 CA208753 $p NCI NIH HHS $2 United States

LZP    __

$a Pubmed-20220425